Inflammatory Marker Tied to Decline in Kidney Function

Share this content:
Inflammatory Marker Tied to Decline in Kidney Function
Inflammatory Marker Tied to Decline in Kidney Function

THURSDAY, Oct. 4, 2018 (HealthDay News) -- High circulating levels of an inflammatory marker, soluble tumor necrosis factor receptor-1 (sTNFR-1), are linked to long-term decline of kidney function, according to a study published online Oct. 4 in the Journal of the American Society of Nephrology.

Pavan K. Bhatraju, M.D., from the University of Washington in Seattle, and colleagues evaluated associations between baseline sTNFR-1 concentrations and 10-year decline in estimated glomerular filtration rate (eGFR) among 2,548 participants in the Multi-Ethnic Study of Atherosclerosis. Serum creatinine concentrations were measured at enrollment and at three, five, and 10 years.

The researchers found that serum sTNFR-1 was inversely associated with baseline eGFR. During a median of 9.3 years of follow-up, 110 participants developed ≥40 percent decline in eGFR. Each standard deviation higher concentration of sTNFR1 was associated with a higher risk of 40 percent eGFR decline (adjusted hazard ratio, 1.43). There was an association between the highest sTNFR-1 tertile and adjusted annualized decline in eGFR (1.94 percent). Results were similar across demographics, hypertension, diabetes, and baseline chronic kidney disease status.

"Our studies identify a novel marker that is strongly related to kidney function decline over time in a large multi-ethnic cohort and suggest follow up studies are warranted to investigate the potential role of sTNFR-1 in the development of kidney function decline," Bhatraju said in a statement.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »